Table 3.

Data available in the ten studies included in the present systematic review

Authors	Year	PET Tracer	Patient-based analysis						Lesion-based analysis
			Patients	mIBG scan +	Sen (%)	PET +	Sen (%)	p	Lesions	mIBG scan +	Sen (%)	PET +	Sen (%)	p
Shulkin et al. [14]	1996	[11C]HED	6	6	100	6	100	N.S	6	6	100	6	100	N.S
Franzius et al. [15]	2006	[11C]HED	7	7	100	7	100	N.S	33	32	97	32	97	N.S
Piccardo et al. [16]	2012	[18F]DOPA	19	11	68	16	95	0.01	136	80	59	118	87	< 0.01
Lu et al. [20]	2013	[18F]DOPA	18	12	75	16	100	0.045	18	12	67	16	89	N.S
Piccardo et al. [13]	2020	[18F]DOPA	18	17	94	18	100	N.S	578	514	89	564	97	< 0.01
Hemrom et al. [17]	2022	[18F]DOPA	46	39	85	42	91	N.S	369	229	62	363	98	< 0.01
Aboian et al. [18]	2021	[124I]mIBG	8	8	100	8	100	N.S	87	32	37	87	100	< 0.01
Pandit-Taskar et al. [22]	2018	[18F]mFBG	5	5	100	5	100	N.S	34	22	64	34	100	< 0.01
Samim et al. [19]	2023	[18F]mFBG	14	12	92	13	100	N.S	52*	18	35	52	100	< 0.001
Wang et al. [21]	2023	[18F]mFBG	40	30	89	34	100	N.S	784	532	67	784	100	< 0.001

mIBG scan + mIBG scintigraphy + SPECT or SPECT/CT true positive findings, PET + PET or PET/CT true positive findings, Sen sensitivity, N.S. non-significant, NR not reported

^*including the primary tumours and the soft-tissue lesions; bone lesions have not been calculated since they were expressed through the SIOPEN score